Dr Manish Singhal

Dr Manish Singhal

Dr Manish Singhal


Medical Oncology

20 yrs+

Indraprastha Apollo Hospitals, Sarita Vihar, Delhi-mathura Road, New Delhi - 110076


Oncology comes as a passion to me rather than a profession. I derived my motivation from my father’s illness, a cancer warrior for the past 18 years. Trained and educated at the apex medical institute of India – All India Institute of Medical Sciences (AIIMS), I have been mentored by the best in cancer care. My expertise spans in all types of chemotherapy, intensive protocols, immunotherapy, hormonal therapy in addition to dealing with oncological emergencies, including medical care of patients.

My ardent interest in academics and willingness to keep up to date got me The Best Exam Award at ESMO (European society of Medical Oncology) Examination 2013 for scoring the top marks globally, making me the first and only Indian to achieve this fame. I was awarded best doctor for year 2014 and 2015 during my tenure at Fortis Hospital Noida for best patient reviews and feedbacks.

I am also the member of Executive Committee of ISMPO (Indian Society of Medical and Pediatrics Oncology), and also ICON (Indian Cooperative Oncology Network), a national body of senior academicians of India. I am also the Joint Secretary of the NCR (national capital region) Oncology Forum and reviewer for South Asia J of Cancer. I held national academic meeting in capacity of organizing secretary for both Oncology Forum and ISMPO in year 2017 and 2016 respectively.

I am the founder and director of an online education and awareness website named which has an impressive reach (more than 100,000 visitors) within 6 months of its inception. My google reviews are the highest for an oncologist in India speak of my dedication to profession and my patients.

I hold deep interest in Breast cancer, Lung Cancer, Gastro-intestinal cancer, Genito-urinary and Lymphomas and myeloma.

I have also developed an online clinical oncology course (Program Director) which gives clinical oncology training to MBBS doctors giving them new job opportunities. This is through Medvarsity online education portal.


The right balance between practice, quality patient care and academics was most achievable at Indraprastha Apollo hospitals New Delhi. With DNB training in medical oncology a large team of 11 surgical oncologist with DNB surgical oncology, 7 radiation oncologist and 6 medical oncologist with the backing of a strong support system of state of the art multi-specialty care and a JCI (Joint commission International) recognition makes Apollo hospital one of its kind institute offering immense opportunity to be a team player, learn and excel. I am presently involved in 6 company sponsored research projects and investigator initiated research proposal. 1. Use of TDM-1 in Metastatic her2 positive breast cancer post 1st line transtuzumab and a taxane. 2. Rituximab in B-cell Lymphoma with various chemotherapy combinations a phase IV study. 3. Ancers-1 Use of canscript in clinical decision making in solid tumors. 4. Povidone Iodine nail solution an RCT to control chemotherapy induced paronychia. 5. Zytiga in prostate cancer – Phase IV study. 6. Ninetidanib in NSCLC phase IV study (under ethical board review). I had 5 publications during this tenure – CML Indian data a Review in IJMPO as 1st author and 2 publications from radiology department as co-authors and 1 publication on Ibrutinib use in Indian subcontinent as co-author and 1 publication again as co-author on HPV positive head and neck cancer – a review.

I had the privilege (one among 20 key national figures on lung diseases) of recording lecture on “Small cell carcinoma lung” (available on line on youtube) for the “e-module of pulmonary medicine” endorsed by Diplomate National board (DNB) and NCCP (National College of Chest Physicians).
I also started an online patient education and awareness and connect platform named which has an impressive reach (more than 100,000 visitors) within 6 months of its inception.

I also had the opportunity to hold the first annual symposium for NCR Oncology Forum at India Habitat Center on 2nd and 3rd Sep 2017 in capacity of the organizing secretary of the meeting.
I regularly hold Highlights of ESMO annual Meeting and San Antonio Breast Cancer Symposium at Delhi involving key opinion leaders of national repute to bring latest updates and their practice adoption in clinical practice relevant to Indian context

My ardent interest in academics and research got me out of a truly corporate hospital network to a research center with an active DNB training program. Dharamshila Hospital is the largest and first NABH accredited Cancer hospital of northern India. In addition to patient care there is an active DNB (medical oncology) training program which takes 2 students per year. Dr Amit a DNB trainee had started his research project under my guidance on triple negative breast cancer, one of my key areas of interest. Personal reasons forced me to shift my work place.
I also had the opportunity to hold the annual symposium for ISMPO at Crowne Plaza, Rohini, New Delhi in Oct 2016 in capacity of co- organizing secretary of the meeting.

  • European Society of Medical Oncology.
  • American society of clinical. Oncology.
  • Indian academy of clinical medicine.
  • Associatio of physicians of india.
  • Indian cooperative Oncology Network.
  • Indian Society of Medical and Pediatric Oncology
  • Oncology Foreum

Awards And Achievements

  • Executive Committee member(ISMPO)
  • Joint Secretary (NCR) Oncology Forem
  • Reviewer for SAJC (south asia Journal 1st and only Indian Gold Medalist.ESMO topper 2013 (European Certified Medical Oncologist)
  • Awarded with the Best Exam Award for ESMO (European society of Medical Oncology) Examination 2013, for scoring highest marks globally.
  • Awarded best doctor for year 2014 and 2015 during my tenure for receiving highest outstanding patient reviews and feedbacks.

Projects and Research

  • Ezetimibe as an adjunct to Atorvastatin in patients of Dyslipidemia – 2004-2006 – Published in Indian Heart Journal
  • Prognostic Value of Plasma High Sensitivity C-Reactive Protein in Patients with Acute Myocardial Infarction – 2005-2007 – Published in Indian Heart Journal
  • Analysis of Peripheral T-Cell Lymphomas: Incidence, Clinical Characteristics, Prognostic Factors, and Treatment Outcomes of 139 cases. – 2007-2010 – Accepted as Abstract in ASCO 2010 # 49701
  • Quantitative estimation of bcr-abl transcripts, To see molecular remission status in patients of Chronic Myeloid Leukemia – 2008-2010 – Completed
  • Iniparib in TNBC – multinational phase 3 study – 2010-2012 – Co-PI
  • Relooking at the need for disclosure – The play of knowing and not knowing in the terminally ill – MPhil Thesis (Ambedkar Univ) Dr Meghna – 2014 – Co-Guide
  • TDM-1 in breast cancer – post taxane and trastuzumab – 2016 – PI (enrolled 5 patients –ongoing)
  • Ancers-1 – Canscript in solid organ malignancies. – 2017 -PI (enrolled 8 patients – ongoing)
  • Povidone Iodine RCT (multinational) for chemotherapy-induced paronychia – 2017 – PI (yet to start enrollment, EC –cleared)
  • Zytiga – in prostate cancer – phase IV -2016-17 – PI (no patient enrolled – competition with cheaper generics)
  • Ninetidanib in NSCLC – phase IV – 2017- PI
  • Atezolizumab with Paclitaxel – International Study Roche Impassion 131. – 2018 – PI
  • Ipatasertib with Paclitaxel _ International Study Roche – 2019 – PI
  • Capmatinib – NSCLC – Novartis international Study – 2020 -PI
  • IGF-1 antibody in breast cancer – Lily sponsored study – 2017-18 -Feasibility evaluation
  • When the Parent becomes the patient – The experience of parenting when diagnosed with cancer. PhD thesis (Delhi University) Dr Meghna – 2015 (ongoing) – Co-Guide


  • Ezetimibe as an adjunct to Atorvastatin in patients of Dyslipidemia.
    Second Author
    Indian Heart Journal 2005; 57:562-564. (Abstract 469)
  • Prognostic Value of Plasma High Sensitivity C-Reactive Protein in Patients with Acute MI
    Fourth Author
    Indian Heart Journal 2006; 58:394-410. (Abstract 79)
  • Efficacy of oxaliplatin, 5 FU and gemcitabine in advanced pancreato-biliary cancer.
    J Clin Oncol, Vol 25, No. 18S (June 20 Supplement), 2007: 15182
  • Primary myositis coinciding with vincristine-induced neuropathic pain and urinary retention in rhabdomyosarcoma: an unusual occurrence.
    First Author
    J Pediatr Hematol Oncol. 2008 Nov;30(11):869
  • Isolated ovarian relapse in a 68 year old female with acute lymphoblastic leukemia – an under reported occurrence.
    First Author
    As Diagnosis in Oncology in J Clin Oncol doi/10.1200/Journal Of Clinical Oncology .2009.24.1398
  • Cure in Breast Cancer, Not Quite Yet But Getting There?
    First Author
    Annals of Oncology 2009; 20:1291.
    As Editorial
  • Extensive Cutaneous Manifestations – Presenting Feature of CML in Second Blast Crisis
    First Author
    Accepted for publication as case report in Indian J Dermat on 21.06.09
  • Heart As The Site of First Relapse in Diffuse Large B-Cell Lymphoma
    First Author
    Letter to Editor in Indian Journal of Cancer 2010; 47: 220-222
  • Beau’s Line
    First Author
    Accepted for publication in Journal of Physicians of India (JAPI), as Pictorial CME 14.03.09
  • Fungal Infection – From Bad to Ugly
    Second Author
    JAPI, 2010; 58:111, as Pictorial CME
  • Childhood Chronic Myeloid Leukemia with Celiac Disease
    First Author
    Pediatric Blood & Cancer as Letter to Editor. 2010; 54:177.
  • T-cell Prolymphocytic leukemia detected in a patient of breast cancer at the time of recurrence
    First Author
    Cases Journal 2010, 3:4 (BM Central)
  • Transplant in Multiple Myeloma
    First Author
    Chapter in Annual book of Haematology Today 2010
    (Prof. MB Aggarwal)
  • Summary of the published Indian data on chronic myeloid leukemia
    First Author
    South Asian J Cancer. 2016; 5(3): 162
  • Human papillomavirus in head and neck cancer in India: Current status and consensus recommend.
    South Asian J Cancer. 2017; 6(3): 93–98.
  • Pertuzumab: Unprecedented benefit in human epidermal growth factor receptor 2-positive breast cancer
    Asian J of Cancer 2015; 1:84
  • Association of pharmacokinetic and metabolic parameters derived using simultaneous PET/MRI: Initial findings and impact on response evaluation in breast cancer
    Eur J Radiol 2017; 92:30
  • NPP case series of initial Ibrutinib experience in India.
    DOI: 10.4103/ijmpo.ijmpo_43_17
  • Current treatment options for Her2-directed therapy in metastatic breast cancer : Indian perspective and practice recommendations.
    Submitted in IJMPO
  • First Indian National Conference on Cervical Cancer Management – Expert Recommendations and Identification of Barriers in Implementation
    Submitted in International Journal of Gynecological cancer
  • #359 Lung Cancer: Beyond EGFR and ALK Dichotomy
    European Lung Cancer Congress
    (Poster) 11-14 April 2018
  • Poster – Annals Pathological Response to weekly Nabpacliaxel andcarboplatin and Anthra based regimen in TNBC
    CoAuthor (2nd)
    ESMO Breast _ Annals 2020
  • Poster – Immunooncology drug challenges in resource constrained countries (Award session)
    Co-Author (2nd)
    ESMO meeting (I/O)
  • Poster – I/O drug toxicity
    Co-Author (2nd)
    ESMo I/O meeting
Quick Book

Request A Call Back